COMMUNIQUÉS West-GlobeNewswire

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

26/02/2025 - 19:30

SARASOTA, FL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today [...]

Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025

26/02/2025 - 20:46

NASHUA, N.H. and CHICAGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and Koios Medical , a leader in AI-driven ultrasound [...]

Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results

26/02/2025 - 22:00

Fourth quarter revenue growth of 28% to $24.7 million 2024 revenue growth of 28% to $90.0 million 68% improvement in adjusted EBITDA in fourth quarter Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE [...]

Inventiva annonce la publication dans Biomedicine & Pharmacotherapy des résultats d'une étude préclinique montrant une amélioration de l'hypertension portale avec le traitement par lanifibranor

26/02/2025 - 22:00

L'étude a démontré que lanifibranor améliorait l'hypertension portale (HTP) dans des modèles murins d'HTP fibrotique et d'HTP non fibrotique préhépatique Il a été observé que lanifibranor réduit la pression portale en [...]

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

26/02/2025 - 22:00

The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and prehepatic non-fibrotic PH Lanifibranor was observed to decrease portal pressure by improving Liver [...]

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

26/02/2025 - 22:01

LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

26/02/2025 - 22:01

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the fourth quarter and fiscal year ended [...]

MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results

26/02/2025 - 22:01

Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0.05 , Respectively Fourth Quarter Adjusted EBITDA¹ was $20 [...]

scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences

26/02/2025 - 22:01

BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric [...]

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

26/02/2025 - 22:02

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026 Company [...]

Health Catalyst Reports Fourth Quarter and Year End 2024 Results

26/02/2025 - 22:03

SALT LAKE CITY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported [...]

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

26/02/2025 - 22:03

– KOMET-001 registrational trial in R/R NPM1 -mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential [...]

Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences

26/02/2025 - 22:05

CHASKA, Minn., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company [...]

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

26/02/2025 - 22:05

FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

26/02/2025 - 22:05

Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer Presented interim data for RLY-2608 + [...]

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

26/02/2025 - 22:05

Conference call to provide corporate updates today at 4:30 pm ET 2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 2023 2024 net income of $28M; Non-GAAP net income of $68M 4Q 2024 net income of [...]

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

26/02/2025 - 22:05

BRISBANE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical [...]

Teladoc Health Reports Full Year and Fourth Quarter 2024 Results

26/02/2025 - 22:05

PURCHASE, NY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the full year ended December 31, 2024 (“Full Year [...]

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

26/02/2025 - 22:13

Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue of $141.8 Million [...]